Search jobs
22-Feb-2021
High prevalence of off-label drug use will boost the systemic scleroderma treatment market, forecast to touch US$ 1.9 Billion by 2025 at a CAGR of 4.5%
Noida, Uttar Pradesh, India, February 22 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global Systemic scleroderma treatment Market is estimated to see healthy growth, pegged at a CAGR of ~4.5% during the forecast period 2020-2025. The supplemental approvals for existing treatment options and the rise of first-in-class therapies are presently under development that creates the growth. The change is further caused by the off-label drug use approved for its symptomatic indications, such as rheumatoid arthritis. However, the high prevalence of off-label drug use and the lack of curative therapies are underlying factors urging interest in rare disease consumption. These factors will boost the targeted biologics and small molecule combination therapies development in the coming years.